Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 6:27 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 13,084 matching trials from the live ClinicalTrials.gov search.
Conditions
Paroxysmal Atrial Fibrillation
Interventions
Ablation Procedure
Device
Lead sponsor
Heart Rhythm Clinical and Research Solutions, LLC
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
21
States / cities
Birmingham, Alabama • Mobile, Alabama • Ventura, California + 17 more
Conditions
Locally Recurrent Breast Cancer, Metastatic Breast Cancer
Interventions
NKTR-102, Treatment of Physician's Choice (TPC)
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
852 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
88
States / cities
Flagstaff, Arizona • Burbank, California • Los Angeles, California + 74 more
Completed Phase 3 Interventional Results available

Apathy in Dementia Methylphenidate Trial 2

NCT02346201
Conditions
Apathy, Alzheimer's Disease
Interventions
Methylphenidate, Placebo
Drug
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
9
States / cities
Phoenix, Arizona • Little Rock, Arkansas • New Haven, Connecticut + 6 more
Conditions
Cardiovascular Disease
Interventions
Olpasiran, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
50 Years to 105 Years
Enrollment
11,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
206
States / cities
Alexander City, Alabama • Birmingham, Alabama • Daphne, Alabama + 168 more
Conditions
Skin and Subcutaneous Tissue Bacterial Infections
Interventions
Delafloxacin, Linezolid, Vancomycin
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
31
States / cities
Mobile, Alabama • Montgomery, Alabama • Buena Park, California + 27 more
Conditions
Multiple Myeloma
Interventions
ASP7487, Velcade, Dexamethasone
Drug
Lead sponsor
University Health Network, Toronto
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Atlanta, Georgia • Chicago, Illinois
Conditions
Prostate Cancer
Interventions
tasquinimod, Placebo
Drug
Lead sponsor
Active Biotech AB
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
34
States / cities
Tucson, Arizona • Oxnard, California • Santa Monica, California + 31 more
Conditions
ALS
Interventions
MT-1186, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
10
States / cities
Rogers, Arkansas • Gainesville, Florida • Atlanta, Georgia + 7 more
Conditions
Congenital Heart Disease
Interventions
MyHeartBaby Program
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Atlanta, Georgia
Completed Not applicable Interventional Results available

Perclose Multi-Access Duplex Ultrasound (DUS) Study

NCT04904809
Conditions
Arrhythmia
Interventions
Perclose ProGlide SMC System and/or Perclose ProStyle SMCR System
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Atlanta, Georgia • Kansas City, Missouri
Conditions
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck
Interventions
tisotumab vedotin, pembrolizumab, carboplatin, cisplatin
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
124
States / cities
Encinitas, California • La Jolla, California • Sacramento, California + 57 more
Conditions
Clostridium Infections, Diarrhea
Interventions
Rifaximin (Xifaxan), Vancomycin
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
63
States / cities
Scottsdale, Arizona • Redlands, California • Longmont, Colorado + 54 more
Conditions
Obstructive Sleep Apnea
Interventions
Negative Pressure Ventilator, Pulmonary Function Testing (PFT), Transcutaneous Phrenic Nerve Stimulation, Percutaneous Phrenic Nerve Stimulation
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunologic Responses to a Live Attenuated Oral Cholera Vaccine

NCT03251495
Conditions
Cholera
Interventions
Vaxchora
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 49 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Untreated Follicular Lymphoma
Interventions
Surovatamig, R-CHOP, R-CVP, BR
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,018 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
62
States / cities
Huntsville, Alabama • Anchorage, Alaska • Phoenix, Arizona + 56 more
Conditions
Metastatic Breast Cancer
Interventions
Sacituzumab Govitecan-hziy, Eribulin, Capecitabine, Gemcitabine, Vinorelbine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
543 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
55
States / cities
Avondale, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 40 more
Conditions
Cancer
Interventions
SynKIR-110, SynKIR-310
Drug
Lead sponsor
Verismo Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2042
U.S. locations
7
States / cities
Denver, Colorado • Atlanta, Georgia • Westwood, Kansas + 4 more
Conditions
Chronic Idiopathic Constipation (CIC)
Interventions
Tenapanor 5 mg BID, Tenapanor 25 mg BID, Tenapanor 50 mg BID, Placebo
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 80 Years
Enrollment
692 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
109
States / cities
Foley, Alabama • Saraland, Alabama • Chandler, Arizona + 98 more
Terminated Phase 2 Interventional Results available

A Study of Ponsegromab in People With Heart Failure

NCT05492500
Conditions
Heart Failure
Interventions
Main cohort (Cohort A): Ponsegromab low dose, Main cohort (Cohort A): Ponsegromab medium dose, Main cohort (Cohort A): ponsegromab high dose, Main cohort (Cohort A): Matched placebo, Open-label, PK Cohort (Cohort B): ponsegromab low dose, Open-label, PK Cohort (Cohort B): ponsegromab medium dose, Open-label, PK Cohort (Cohort B): ponsegromab high dose, Optional Cohort C: Ponsegromab low dose, Optional Cohort C: Matched placebo, Optional Cohort D: Ponsegromab high dose, Optional Cohort D: Matched placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
22
States / cities
Fairhope, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 13 more
Conditions
Diabetes Mellitus Type 2
Interventions
placebo, taspoglutide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
29
States / cities
Bermuda Dunes, California • La Jolla, California • Los Angeles, California + 26 more
Conditions
Retinitis Pigmentosa
Interventions
Not listed
Lead sponsor
Second Sight Medical Products
Industry
Eligibility
25 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
17
States / cities
Los Angeles, California • Denver, Colorado • Miami, Florida + 13 more
Conditions
Binge-Eating Disorder
Interventions
ACT-539313, Placebo
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
30
States / cities
Beverly Hills, California • Encino, California • Garden Grove, California + 24 more
Completed Not applicable Interventional Results available

Carotid Revascularization Endarterectomy Versus Stenting Trial

NCT00004732
Conditions
Atherosclerosis, Stroke, Carotid Stenosis, Cerebral Infarction, Myocardial Infarction
Interventions
Carotid Endarterectomy (CEA), Carotid Artery Stenting (CAS)
Procedure · Device
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
2,502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2016
U.S. locations
106
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 84 more
Conditions
Ulcerative Colitis
Interventions
Adacolumn Apheresis System
Device
Lead sponsor
Otsuka America Pharmaceutical
Industry
Eligibility
18 Years to 75 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
26
States / cities
Phoenix, Arizona • Burbank, California • San Francisco, California + 22 more